front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |review

These data are presented in the cited manuscript. Individuals who do not carry the mutation but have been exposed to OCP have a ~4-fold increased risk of VT than those who do not carry the mutation and were not exposed to OCP. Those who carry the mutation but have not used OCP have a ~7-fold increased risk of VT compared to those do not carry the mutation or used OCP. However, the risk for individuals with the mutation and exposure to OCP is very high, ~35 times greater than the risk for women with neither the mutation or exposure to OCP.